一品红：药品研发具有周期长、投入高、风险大等特点

Group 1 - The core viewpoint of the article is that Yipinhong has received clinical trial approval for its small molecule AM-001 from both the China National Medical Products Administration (CDE) and the U.S. Food and Drug Administration (FDA) [2] - The product AM-001 is a MRGPRX2 receptor modulator intended for the treatment of autoimmune diseases such as atopic dermatitis and urticaria [2] - The drug development process is characterized by long cycles, high investment, and significant risks, prompting the company to advise investors to make cautious decisions [2]